Adaptimmune (ADAP) is expected to provide regulatory and developmental updates on its pipeline programs in its upcoming earnings release, given the absence of marketed products in its portfolio.

Adaptimmune (ADAP) surges on the completion of the rolling submission, with the FDA seeking approval for its most advanced pipeline candidate as the first engineered cell therapy for solid tumors.

According to data from Benzinga Pro, ADAP has a 52-week high of $2.05 and a 52-week low of $0.42. ADAP Adaptimmune Therapeutics PLC. $0.2527-1.29 % Stock Score Locked: Want to See it?

A high-level overview of Adaptimmune Therapeutics plc (ADAP) stock. View (ADAP) real-time stock price, chart, news, analysis, analyst reviews and more.

We are initiating coverage of Adaptimmune Therapeutics plc ADAP with a 12-month price target of $3.00, translating into sizeable upside from the stock's current price. Adaptimmune designs ...

Adaptimmune is down after merging with TCR2, while TCR2 is up. Read more to see why the merger with TCRR stock looks like a smart deal for ADAP stock.